Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

Peking Union Medical College50 enrolled

Overview

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hidradenitis Suppurativa (HS)

Interventions

SecukinumabDRUG

secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * age ≥18 years * diagnosis of moderate-to-severe HS with Hurley stage II or III * Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules * inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors Exclusion Criteria: * active infections (e.g., viral hepatitis, active tuberculosis) * use of other biologics or systemic immunosuppressants within the past three months * severe organ dysfunction (e.g., hepatic or renal failure) * any other conditions that might affect study results

Outcomes

Primary Outcomes

Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)

a ≥50% reduction in the combined count of inflammatory nodules and abscesses from baseline, without an increase in the number of abscesses or draining tunnels

Time frame: From enrollment to the end of treatment at Week 12

Secondary Outcomes

Dermatology Life Quality Index

Time frame: From enrollment to the end of treatment at week 12